Radiolabeled antibodies for therapy of infectious diseases

There is a growing need for alternatives to conventional antibiotics for the treatment of infectious diseases. The number of bacterial pathogens that are resistant even to the most powerful antibiotics is growing each year. HIV remains an incurable disease more than 30 years since its identification. Since 1979 there has been a >200% increase in the annual number of cases of invasive fungal infections in the United States. To exacerbate these problems, the number of patients who cannot fight infections because of impaired immunity is growing and includes HIV patients, patients who have been through cancer chemotherapy, and organ transplant recipients.